Kornimate/medical-research-clean huggingface dataset:
continuous infusion of ropivacaine hydrochloride in reducing pain after surgery in patients with bladder cancer

Conditions: Bladder Carcinoma; Post-operative Pain

Summary: this randomized phase iv trial studies how well the continuous infusion of ropivacaine hydrochloride works in reducing pain after surgery in patients with bladder cancer. ropivacaine hydrochloride is an anesthetic drug used to decrease pain by numbing an area of the body without putting the patient to sleep. continuous infusion of ropivacaine hydrochloride may reduce pain and improve the quality of life for patients after bladder surgery.

primary objectives: i. to determine if continuous infusion of local anesthesia (cila) decreases post-operative pain after radical cystectomy (rc). ii. to determine if cila reduces narcotic requirements after rc. secondary objectives: i. to determine if cila decreases length-of-stay after rc. ii. to determine if cila improves patients satisfaction with post-operative pain control after rc. outline: patients are randomized to 1 of 2 arms. arm i: patients receive ropivacaine hydrochloride intravenously (iv) continuously over 72 hours after radical cystectomy. arm ii: patients receive normal saline (placebo) iv continuously over 72 hours after radical cystectomy. after completion of study, patients are followed up within 30 days.

Eligibility criteria:
inclusion criteria: * undergoing elective open radical cystectomy * ability to understand and the willingness to sign a written informed consent exclusion criteria: * allergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide type of local anesthesia * allergy or adverse reaction to local anesthesia catheter * additional surgery at the same time as rc (e.g. nephroureterectomy) * coagulopathy * thrombocytopenia * local or systemic infection * pregnancy * chronic hepatic disease * use of type iii antiarrhythmics (e.g. amiodarone) * history of chronic pain and/or daily opioid use
phase iv study to compare efficacy and safety of plavix 75mg with astrix 100mg and closone

Conditions: Coronary Artery Disease

Summary: the aim of this study is to prove non-inferiority of closone to the combination treatment of plavix with astrix.


Eligibility criteria:
inclusion criteria: * subjects under a stable condition after post-percutaneous coronary artery intervention over three months * 20\~86 years old * willing to adhere to protocol requirements and sign a informed consent form exclusion criteria: * subject who did not undergo or failed drug-stent implantation * subjects who took an anti-coagulant, anti-thrombotic regularlly( ≥ 2weeks in a month) before the study, or plan to have continuous treatment during the study(except aspirin alone or combination of aspirin and clopidogrel) * subjects with a history of substance or alchol abuse * subjects with a history of hypersensitivity to clopidogrel, aspirin or other nsaids * subjects having aspirin or other nsaids-induced asthma or history * subjects with severe hepatopathy(ast and alt \> 5 times the upper limit of normal) * subjects with severe nephropathy(cr \> 3 times the upper limit of normal) * subjects with hemorrhage like gastric ulcer, intracranial hemorrhage etc. * subjects with high risk of hemorrhage like blood coagulation disorders, uncontrolled severe hypertension, active bleeding, history of severe bleeding * subjects who are pregnant, breastfeeding * subjects not using medically acceptable birth control * subjects who are unsuitable to take the investigational product due to a medical/mental condition * subjects inherently having galactose malobsorption, lactase deficiency or glucose-galactose malobsorption
benefits of drinking clear fluids until called to the operating room in adult surgical patients

Conditions: Anesthesia; Thirst; Due to Deprivation of Water; Aspiration

Summary: the purpose of this study is to show if - compared to standard practice - allowing adults undergoing surgical procedures under anaesthesia care to drink clear fluids up to a volume of 200 ml between 2 h prior to the operation and the call to operation room (approximately 30 min prior to anaesthesia induction) will decrease patient thirst and increase patient satisfaction.


Eligibility criteria:
inclusion criteria: 1. adult patients (≥ 18 years) 2. american society of anesthesiologists (asa) physical status classification i-iii 3. undergoing surgical procedure under anaesthesia care: general anaesthesia, regional anaesthesia, combined anaesthesia or monitored anaesthesia care. the proportion of patients undergoing general or combined anaesthesia is aimed to exceed 75% exclusion criteria: 1. absolute indication for rapid sequence induction including but not limited to: 1. bowel obstruction including ileus 2. stricture and oesophageal disorders including achalasia 3. recent polytrauma or trauma of the upper gastrointestinal tract 4. acute abdomen/peritonitis including active gastrointestinal bleeding 2. relative indication for (modified) rapid sequence induction includes, but is not limited to: 1. symptomatic gastroesophageal reflux disease, independent of food intake and persistent under medical treatment (ppi) 2. hiatus hernia or upside down stomach 3. upper gastrointestinal tumour 4. history of upper gastrointestinal surgery (oesophageal, gastric, duodenum, pancreatic) 5. medically confirmed gastroparesis 6. severe obesity, defined as body mass index ≥ 40 kg/m2 3. dysphagia 4. renal replacement therapy 5. fluid restriction therapy 6. pregnancy 7. expected need for postoperative mechanical ventilation

Keywords: surgery postoperative nausea and vomiting delirium dehydration satisfaction, patient headache
effects of core strengthening and pnf pattern on static balance and plantar pressure in chronic stroke patients

Conditions: Chronic Stroke

Summary: stroke is a neurological disease characterized by neurological deficits caused by insufficiency of blood supply to brain. disruption of blood supply to brain can be due to blockage of blood supply (ischemic) or leakage of blood in brain due to rupture of blood vessel (hemorrhagic). 90.5% of global occurrence of stroke was subjected to modifiable risk factors according to global burden of disease study. this study aims to compare the effects of core strengthening and proprioceptive neuromuscular facilitation on static standing balance and plantar pressure in chronic stroke patients.

background: stroke is a neurological disease characterized by neurological deficits caused by insufficiency of blood supply to brain. disruption of blood supply to brain can be due to blockage of blood supply (ischemic) or leakage of blood in brain due to rupture of blood vessel (hemorrhagic). 90.5% of global occurrence of stroke was subjected to modifiable risk factors according to global burden of disease study. objective: to compare the effects of core strengthening and proprioceptive neuromuscular facilitation on static standing balance and plantar pressure in chronic stroke patients. methodology: 73 patients were enrolled in this study, 37 patients were assigned into control group while 36 participants were assigned into experimental group. control group received routine physical therapy while experimental group received core strengthening and proprioceptive neuromuscular technique. static component of berg balance scale and podata stabiliometeric plate was used for plantar pressure and measurement of balance respectively.

Eligibility criteria:
inclusion criteria: * age (45-60 years) * score of 9 or higher on static component of berg balance scale * having score of equal or less than 2 on modified ashworth scale * having score of greater than or equal to 24 on mini mental state examination. * first ever episode of stroke * duration of stroke greater than 6 months * both genders exclusion criteria: * concurrent orthopedic conditions that may hamper standing * relevant psychiatric disorders that may prevent from following instructions. * medical drugs that may influence intervention * conditions contraindicating physical activity * use of cardiac pace maker.

Keywords: core strengthening plantar pressure
a kidney transplant study to look at the effects of taking fixed doses of cellcept versus taking doses of cellcept based on the concentration of cellcept in the blood when taking full or reduced dose calcineurin inhibitors

Conditions: Kidney Transplantation; Delayed Graft Function

Summary: this research is being done to study the effects (good and bad) of taking cellcept based on blood concentrations versus taking a fixed dose of cellcept without measuring the blood concentration. cellcept is one of the three immunosuppressant drugs (drugs that suppress the immune system) which will be taken as part of this kidney transplant study. cyclosporine or tacrolimus and corticosteroids are the two other drugs which will be taken.

this study is an open label study, which means the participant will know which drugs they are on. participants will be put in one of three groups within 24 hours of the participant's transplant. the participant will be asked to return throughout the 24 months for physical exams, blood and urine tests.

Eligibility criteria:
inclusion criteria: * participants must be between 18 and 70 years of age and should be receiving their first or second kidney transplant.

Keywords: kidney transplant
rct: the effect of held position during kangaroo care on physiological parameters of premature infants

Conditions: Extreme Prematurity; Extremely Low Birth Weight; Very Low Birth Weight Infant; Premature Birth

Summary: the goal of this superiority crossover randomised controlled trial is to investigate whether there is an optimal position at which to perform kangaroo mother care (kmc) in extremely preterm infants in the nicu. the main question it aims to answer is: 1) is there an optimal position for an infant to be held during kmc and 2) to optimise benefits for infants receiving kmc. participants will be: 1) randomised into two groups which determine which angle they will start at first, 2) assessed over two hour-long sessions on different days with a change in the angle at the 30 minute point, 3) monitored using a massimo nirs machine which will record oxygen saturations, cerebral nirs values and heart rates, and 4) monitored for any episodes of desaturations and bradycardias during this time. participants will then be assessed beginning with the the other angle first on a different day. the researchers will then compare the two groups to see if being held at a 30 degrees during kmc is superior to being held at 60 degrees in terms of physiological stability.

in this proposed study the investigators will examine whether there is an optimal position in which to perform kmc. this will be performed by evaluating cerebral oxygenation with near infrared spectroscopy (nirs). cerebral near-infrared spectroscopy (nirs) is used as a non-invasive assessment of cerebral oxygenation and cerebral hemodynamics. nirs gives an estimation of the regional cerebral tissue oxygenation via a probe attached to the baby's forehead. it is minimally invasive and won't interrupt any of baby's cares or interrupt time with parents. the investigators will use nirs to specifically examine whether there is a difference in physiological parameters between being held when the mother/father is at a 30 degree or 60 degree angle on the bedside recliner and whether better oxygenation is associated with one position over another. currently there are no studies assessing the optimal position to carry out kmc in neonatal units. this study proposes to help answer a question which has not yet been answered in the literature.

Eligibility criteria:
inclusion criteria: * ex-premature infants who are a minimum of 28 weeks corrected gestational age * minimum weight at assessment for entry to study 600g * signed informed consent form exclusion criteria: * corrected gestational age under 28 weeks * known neurological anomalies (not intraventricular haemorrhage) * known orthopaedic conditions * known chromosomal anomalies

Keywords: kangaroo mother care nirs oxygen saturation heart rate nicu
oxidative stress and microcirculation in patient with hepatic failure undergoing liver support treatment

Conditions: Liver Failure; Critical Care

Summary: background: in patients undergoing hemodialysis or hemofiltration will suffer from the injury of reactive oxidative species. oxidative stress will affect cell membrane, protein, and dna. it will damage the cell and result in organ dysfunction. we believe that in patients, who have acute hepatic failure, undergoing plasma exchange or molecular absorbent recirculating system for bridge therapy will suffer from the injury of reactive oxidative species, too. it will damage the kidney, lung, cerebral cortex, and other organs. it may result in death before the recovery of liver function or undergoing liver transplantation. aims: 1. investigate the severity of oxidative stress and risk factors of high oxidative stress in acute hepatic failure patient undergoing plasma exchange or molecular absorbent recirculating system. 2. investigate the microcirculation status and risk factors in acute hepatic failure patient undergoing plasma exchange or molecular absorbent recirculating system. 3. study the relationship between oxidative stress and microcirculation status. 4. study the correlation between oxidative stress and prognosis. 5. study the correlation between microcirculation status and prognosis.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old 2. patients with acute deterioration on chronic liver failure, who required liver support treamtment 3. patients with acute liver failure due to acute hepatitis, who reauired liver support treatment 4. patients with acute liver dysfunction within 7 days after liver transplantation, who required liver support treatment exclusion criteria: 1. age \> 70 years old 2. cancer, not curable 3. patients who had used of antioxidant therapy within 24 hours before study 4. patients who had received hyperbaric oxygen therapy within 24 hours before study 5. patients who had received peroxide treatment within 24 hours before study

Keywords: liver support treatment
maxima study: a study of maintenance therapy with mabthera (rituximab) in patients with non-hodgkin's lymphoma.

Conditions: Non-Hodgkin's Lymphoma

Summary: this single arm study will evaluate the safety and efficacy of mabthera maintenance therapy following a mabthera-containing induction regimen in first line or relapsed patients with follicular non-hodgkin's lymphoma. all patients will receive mabthera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. the anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * histologically confirmed grade 1, 2 or 3a follicular non-hodgkin's lymphoma; * patients who have received adequate (\>=8 cycles) induction therapy with mabthera as first line treatment, or treatment for relapsed disease; * demonstrated partial or complete response to induction therapy. exclusion criteria: * stable or progressive disease after most recent induction therapy; * transformation to high grade lymphoma; * patients with prior or concomitant malignancies, except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.
prognostic value of myosteatosis and creatinine-to-cystatin c ratio in patients with pancreatic ductal adenocarcinoma

Conditions: Skeletal Muscle Radiodensity; Myosteatosis; Scr/CysC Ratio; Pancreatic Ductal Adenocarcinoma

Summary: pancreatic ductal adenocarcinoma (pdac) is a dismal disease with a 5-year survival rate as low as 6%. it causes body composition changes and many patients develop muscle loss with disease progression. computed tomography (ct) is a common, noninvasive method of muscle assessment.known as myoesteatosis,low muscle radiodensity is reflective of intermuscular adipose tissue that influences survival outcomes in patients with cancer.serum creatinine (scr) and cystatin c (cysc) are usually employed to estimate renal function in clinical practice. scr is a metabolic waste product produced by creatine in skeletal muscle. cysc can be produced by all nucleated cells in the body at a constant production rate. cysc is used as an endogenous marker to reflect the glomerular filtration rate. some studies have supported that the scr/cysc ratio (ccr) is a simple and inexpensive measure that can be used to evaluate the skeletal muscle mass of patients with malignancies, such as gastric cancer. therefore, the purpose of the present study is to explore the association between ccr and myosteatosis upon diagnosis of pdac, specially whether the co-occurrence of these factors could predict survival outcomes.preoperative assessment of muscle quality may be valuable for treatment planning and optimization of nutritional support. this retrospective study enrolls patients who underwent surgery for pdac, from january 2016 to december 2021. patients will be divided into myosteatosis and non-myosteatosis groups. clinical and imaging data are collected.the study does not have any intervention measures and harm to subjects.

inclusion criteria: a）aged between 18 and 75; b) pancreatic ductal adenocarcinoma confirmed by biopsy or postoperative pathology; c) ct and renal function related data within 1 month before operation; d) voluntarily participate in this study and have informed consent. exclusion criteria: * pancreatic malignant tumors of other pathological types or other malignant tumors; * received local or systemic radiotherapy and chemotherapy before operation; ③ with severe metabolic diseases such as decompensated cirrhosis, nervous system diseases and muscle degenerative diseases; ④ absent of preoperative imaging or clinical data;

Eligibility criteria:
inclusion criteria: * a） aged between 18 and 75; b) pancreatic ductal adenocarcinoma confirmed by biopsy or postoperative pathology; c) ct and renal function related data within 1 month before operation; d) voluntarily participate in this study and have informed consent. exclusion criteria: * ① pancreatic malignant tumors of other pathological types or other malignant tumors; * received local or systemic radiotherapy and chemotherapy before operation; * with severe metabolic diseases such as decompensated cirrhosis, nervous system diseases and muscle degenerative diseases; ④ absent of preoperative imaging or clinical data; ⑤ lost interviewers.
comparison of accuracy and functional outcome between robotic and gyroscopic assisted surgery in primary tka

Conditions: Knee Arthropathy

Summary: a randomized controlled trial was conducted with 72 participants who had moderate knee osteoarthritis (kellgren and lawrence grade 2-3). the patients were randomly assigned to either the robotic-assisted or gyroscopic-assisted group. baseline characteristics, including age, body mass index, length of stay, and estimated blood loss, were recorded. the primary outcome measure was the accuracy of the hip knee angle, measured by scannogram film preoperatively and postoperatively at 3 months. secondary outcomes included functional outcomes (koos, oxford knee score, eq-5d-5l, range of motion) assessed preoperatively and postoperatively at 3 months, as well as at 6 months postoperatively.

introduction: primary total knee arthroplasty is considered the gold standard treatment for end-stage osteoarthritis of the knee. the primary objective of this surgical procedure is to restore mechanical alignment. at siriraj hospital, we employ technology to enhance the accuracy of our surgical procedures. the purpose of this study is to compare the accuracy of robotic-assisted surgery (rosa) and gyroscope-based surgery in primary total knee arthroplasty. methods: a randomized controlled trial was conducted with 72 participants who had moderate knee osteoarthritis (kellgren and lawrence grade 2-3). the patients were randomly assigned to either the robotic-assisted or gyroscopic-assisted group. baseline characteristics, including age, body mass index, length of stay, and estimated blood loss, were recorded. the primary outcome measure was the accuracy of the hip knee angle, measured by scannogram film preoperatively and postoperatively at 3 months. secondary outcomes included functional outcomes (koos, oxford knee score, eq-5d-5l, range of motion) assessed preoperatively and postoperatively at 3 months, as well as at 6 months postoperatively.

Eligibility criteria:
inclusion criteria: * primary osteoarthritis knee with indicated for total knee replacement * age equal or more than 55 years old exclusion criteria: * revision surgery * deformity greater than 15º * intra/post operative complication
the use of transcranial direct current stimulation (tdcs) in adults with developmental disabilities

Conditions: Aggression

Summary: aggressive behaviours are highly prevalent among people with developmental disabilities, both in community and inpatient or residential settings, with adverse consequences for the individuals involved and others. some predictive factors, particularly impulsivity, are dynamic with neurobiological underpinnings, and as such amenable to change or neuromodulation using non-invasive brain stimulation techniques. with this in mind, we designed an experimental protocol to determine the efficacy of transcranial direct current stimulation (tdcs) as a non-invasive brain stimulation technique to reduce impulsivity and aggression associated with developmental disability.

this study aims to assess the efficacy of anodal tdcs in modulating rapid response impulsivity (rri) and reducing incidents of aggression in people with developmental disabilities is residential or hospital settings. using a single blind, parallel arms, randomized controlled trial design, adults (n=60) aged 18 to 65 with developmental disabilities, who have a history of impulsivity leading to aggression, will be randomised to receive either repetitive anodal or sham tdcs. enrolled participants will receive either three treatment sessions of tdcs or sham tdcs. behavioural and impulsivity will be measured before and immediately after treatment, one week, and one month after treatment end. data will be analysed in spss using repeated measures anova.

Eligibility criteria:
inclusion criteria: * adults aged 18-64 years * diagnosis of a developmental disability * history of one or more incidents of aggression in the last month * consent to participate in the trial by the individual or their substitute decision maker exclusion criteria: * history of epilepsy or seizures * history of acquired brain injury * having metal in the brain/skull, e.g. splinters, fragments or clips * having a cochlear implant * having an implanted neuro-stimulator (e.g. direct brain stimulation, epidural/subdural stimulation, vagal nerve stimulation) * history of brain surgery of procedure * history of severe adverse reaction to tdcs * having a cardiac pacemaker or intracardiac lines * current alcohol or drug misuse * having a sensitive scalp